Is ACRS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ACRS. It does not provide personalized investment advice.

ACRS (Aclaris Therapeutics, Inc.) Stock Analysis - Financials

Aclaris Therapeutics, Inc. (ACRS) is a publicly traded Healthcare sector company. As of September 1, 2026, ACRS trades at $5.99 with a market cap of $884.67M and a P/E ratio of -10.25. ACRS moved -0.74% today. Year to date, ACRS is +101.00%; over the trailing twelve months it is +213.47%. Its 52-week range spans $1.05 to $6.60. Analyst consensus is strong buy with an average price target of $12.50. Rallies surfaces ACRS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are ACRS's key financials?

ACRS financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. ACRS recently traded at $5.99. Market cap is $884.67M. P/E ratio is -10.25. Revenue is $8.22M.

ACRS Key Metrics

Key financial metrics for ACRS
Metric	Value
Price	$5.99
Market Cap	$884.67M
P/E Ratio	-10.25
EPS	$-0.58
Dividend Yield	0.00%
52-Week High	$6.60
52-Week Low	$1.05
Volume	836.25K
Avg Volume	0
Revenue (TTM)	$8.22M
Net Income	$-75.74M
Gross Margin	79.52%

ACRS Analyst Consensus

4 analysts cover ACRS: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $12.50.

Common questions about ACRS

What are ACRS's key financials?: ACRS financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. ACRS recently traded at $5.99. Market cap is $884.67M. P/E ratio is -10.25. Revenue is $8.22M.
Is ACRS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ACRS. It does not provide personalized investment advice.